Finance

Lists
CRBU:NASDAQ
Caribou Biosciences Inc
၀.၄၆ US$
+၁.၀၀%
(+၀.၀၀၄၆) 1D
၀.၄၅ US$
-၂.၉၃% (-၀.၀၁၄)
After hours
Closed: အောက် ၁၅, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRBU...
Open
၀.၄၆ US$
High
၀.၄၈ US$
Low
၀.၄၅ US$
Mkt. cap
၄.၉၈ ကုဋေ
Avg. vol.
၃.၇၇ သန်း
Volume
၂.၈၈ သန်း
52-wk high
၃.၅၃ US$
52-wk low
၀.၄၄ US$
EPS
-၁.၀၈ US$
Beta
၂.၃၁
Shares outstanding
၁၀.၇၂ ကုဋေ
No. of employees
၉၇
Open
၀.၄၆ US$
High
၀.၄၈ US$
Low
၀.၄၅ US$
Mkt. cap
၄.၉၈ ကုဋေ
Avg. vol.
၃.၇၇ သန်း
Volume
၂.၈၈ သန်း
52-wk high
၃.၅၃ US$
52-wk low
၀.၄၄ US$
EPS
-၁.၀၈ US$
Beta
၂.၃၁
Shares outstanding
၁၀.၇၂ ကုဋေ
No. of employees
၉၇
News stories
From web sources and news partners
조선일보
조선일보
·
ပြီးခဲ့သည့် ၁ နာရီ
Exclusive: Solidigm Hires Trump Allies for Nasdaq Listing
Yahoo Finance
Yahoo Finance
·
ပြီးခဲ့သည့် ၅၅ မိနစ်
Grayscale Says Bitcoin’s Volatility Falls to 43%, Now Within S&P 500 Range
WSJ
WSJ
·
ပြီးခဲ့သည့် ၂ နာရီ
Stocks Gain as Treasury Yields Give Back Some Recent Gains
About Caribou Biosciences Inc
CEO-
Employees၉၇
Founded၂၀၁၁ ဇန် ၁
HeadquartersBerkeley, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to CRBU in the past 3 months
Buy
Buy
2
Hold
4
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for CRBU in the last 3 months.
Highest
Current ၀.၄၆ US$
၈.၀၀ US$ (+၁,၆၂၁.၅၄%)
Average
၃.၇၅ US$ (+၇၀၆.၉၇%)
Lowest
၁.၀၀ US$ (+၁၁၅.၁၉%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Hold
Downgraded
-
-
10/08/2026
Daina Graybosch
Leerink Partners
Hold
Downgraded
၁.၀၀ US$
+၁၁၅.၂%
10/07/2026
Luca Issi
RBC Capital
Hold
Downgraded
၁.၀၀ US$
+၁၁၅.၂%
10/06/2026
Leah R. Cann
Brookline Capital Markets
Hold
Downgraded
-
-
10/06/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
၅.၀၀ US$
+၉၇၆%
08/14/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
၈.၀၀ US$
+၁,၆၂၁.၅%
08/13/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
၁၃.၀၀ US$
+၂,၆၉၇.၅%
03/09/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
၇.၀၀ US$
+၁,၄၀၆.၃%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
၄.၀၀ US$
+၇၆၀.၈%
03/06/2026
William Maughan
Clear Street
Buy
Maintained
၁၃.၀၀ US$
+၂,၆၉၇.၅%
03/06/2026
Last report
၂၀၂၆ ဩ ၁၃
Fiscal period
Q2 2026
-၀.၂၄ US$ / -၀.၃၁ US$
+၂၁.၇၄%beat
Revenue / Est. (USD)
၁.၅၀ သန်း / ၂.၂၅ သန်း
-၃၃.၂၅%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၂.၂၀ သန်း
၃.၉၄ သန်း
၂.၄၀ သန်း
၁.၅၀ သန်း
Cost of goods sold
၂.၂၄ ကုဋေ
၂.၃၈ ကုဋေ
၂.၀၆ ကုဋေ
၁.၈၉ ကုဋေ
Cost of revenue
၂.၂၄ ကုဋေ
၂.၃၈ ကုဋေ
၂.၀၆ ကုဋေ
၁.၈၉ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၉.၂၀ သန်း
၈.၅၈ သန်း
၈.၀၇ သန်း
၇.၉၀ သန်း
Operating expense
၉.၂၀ သန်း
၈.၅၈ သန်း
၈.၀၇ သန်း
၇.၉၀ သန်း
Total operating expenses
၃.၁၆ ကုဋေ
၃.၂၄ ကုဋေ
၂.၈၇ ကုဋေ
၂.၆၈ ကုဋေ
Operating income
-၂.၉၄ ကုဋေ
-၂.၈၅ ကုဋေ
-၂.၆၃ ကုဋေ
-၂.၅၃ ကုဋေ
Other non operating income
-
၄.၂၀ သောင်း
-
-
EBT including unusual items
-၂.၇၅ ကုဋေ
-၂.၇၀ ကုဋေ
-၂.၅၁ ကုဋေ
-၂.၄၃ ကုဋေ
EBT excluding unusual items
-၂.၇၅ ကုဋေ
-၂.၇၀ ကုဋေ
-၂.၅၁ ကုဋေ
-၂.၄၃ ကုဋေ
Income tax expense
-
-၅.၅၀ သိန်း
-
-
Effective tax rate
-
၂.၀၃%
-
-
Other operating expenses
-
-
-
-
Net income
-၂.၇၅ ကုဋေ
-၂.၆၅ ကုဋေ
-၂.၅၁ ကုဋေ
-၂.၄၃ ကုဋေ
Net profit margin
-၁,၂၅၃.၃၂%
-၆၇၂.၁၁%
-၁,၀၄၆.၅၂%
-၁,၆၁၉.၈၈%
Earnings per share
-
-
-၀.၂၆
-၀.၂၄
Interest and investment income
၁.၈၅ သန်း
၁.၃၇ သန်း
၁.၂၀ သန်း
၁.၀၆ သန်း
Interest expense
-
-
-
-
Net interest expenses
၁.၈၅ သန်း
၁.၃၇ သန်း
၁.၂၀ သန်း
၁.၀၆ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၂.၈၈ ကုဋေ
-၂.၇၈ ကုဋေ
-၂.၅၆ ကုဋေ
-၂.၄၇ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ